Novartis Reorganizes Its US Pharma Unit, Replacing CEO And Slashing 250 Jobs
This article was originally published in The Pink Sheet Daily
Executive Summary
The drug maker creates four business units, including primary care, which remains "critically important" to future growth.
You may also be interested in...
Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs.
Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs.
Novartis Names Andre Wyss To Run Its North American And U.S. Pharma Business
The 25-year Novartis veteran succeeds Ludwig Hantson, who was simultaneously named as corporate vice president at Baxter International.